Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis.

about

Investigational drugs in clinical trials for Hidradenitis Suppurativa.Tofacitinib: A New Oral Therapy for Psoriasis.Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management.

P2860

Q47393458-B953441E-63C0-4B15-A8D2-9C1A2100D2B8 Q47623085-69BB6487-E1C9-4532-A12A-6D5F0AEC6DC1 Q55152453-0F7C1416-2259-4628-A4FE-0D64D98955AC

P2860

Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis.

Item

http://www.wikidata.org/entity/Q39361316

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis.

@en

Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis.

@nl

type

Item

label

Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis.

@en

Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis.

@nl

prefLabel

Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis.

@en

Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis.

@nl

P1476

Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis.

@en

P2093

Luis Puig

http://www.w3.org/2001/XMLSchema#string

Tiago Torres

http://www.w3.org/2001/XMLSchema#string

P2860

Roflumilast: a review of its use in the treatment of COPD

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.

Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature.

Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors.

Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis.

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)

The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)

A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial.

Drug safety evaluation of apremilast for treating psoriatic arthritis.

A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast.

P2888

s40257-017-0302-0

P31

scholarly article

P356

10.1007/S40257-017-0302-0

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28597182

http://www.w3.org/2001/XMLSchema#string

Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis.

about

P2860

P2860

Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P31

P356

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P31

P356

P577

P698